# Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma

> **NCT06517017** · PHASE2 · RECRUITING · sponsor: **University of Utah** · enrollment: 40 (estimated)

## Conditions studied

- Multiple Myeloma
- Plasma Cell Leukemia

## Interventions

- **DRUG:** Isatuximab

## Key facts

- **NCT ID:** NCT06517017
- **Lead sponsor:** University of Utah
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-09
- **Primary completion:** 2026-11
- **Final completion:** 2027-11
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-11-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06517017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06517017, "Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06517017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*